CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma...
Phase 2
Chapel Hill, North Carolina, United States of America and 2 other locations
Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil,...
Phase 2
Chapel Hill, North Carolina, United States and 3 other locations
DS-3201b is an experimental drug that is being investigated in clinical research.Adults with non-Hodgkin lymphoma (NHL) may be able to join ...
Phase 1
Durham, North Carolina, United States and 20 other locations
and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...
Phase 2
Chapel Hill, North Carolina, United States and 8 other locations
(R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current...
Phase 2
Durham, North Carolina, United States and 7 other locations
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...
Phase 2
Durham, North Carolina, United States and 59 other locations
treatment of advanced classical Hodgkin lymphoma(HL)...
Phase 3
Raleigh, North Carolina, United States and 215 other locations
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...
Phase 2
Durham, North Carolina, United States and 94 other locations
comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in patients with primary central nervous system lymphoma...
Phase 1, Phase 2
Durham, North Carolina, United States and 41 other locations
safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma...
Phase 2
Durham, North Carolina, United States and 83 other locations
Clinical trials
Research sites
Resources
Legal